{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:16:57Z","timestamp":1794035817625,"version":"4.8.0"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>The SARS-CoV-2 virus has mutated over time, resulting in variations of circulating viral variants, which may impact the virus\u2019s properties, such as transmission or the severity of symptoms. Thus, there is a need for comprehensive approach less dependent of viral variants. For that purpose, we have employed the innovative and unique Resonant Recognition Model (RRM) to identify the common characteristics of all variants of SARS-CoV-2 virus and based on these characteristics, we have explored the possibility to develop approach against SARS-CoV-2 infection, less dependent on viral variants. This paper is a continuation of our previous research, where we have used the RRM model to design <jats:italic>de novo<\/jats:italic> peptide CovA, capable to prevent SARS-CoV-2 interaction with ACE2 receptor on host cells. Using Inhibitor Screening Assay Kits and viral replication in SARS-CoV-2\/Vero E6 cells model, it has been previously shown that CovA can prevent viral interaction with receptor and viral replication in host cells. This test has been done on Wuhan variant only. Here, we have tested this RRM designed peptide CovA for efficiency with some other different SARS-CoV-2 variants. It has been shown here, that CovA act on all tested viral variants, but with different efficiency. Apart from representing the basis of new COVID-19 drugs discovery, this research once again presents the ability of RRM model to design <jats:italic>de novo<\/jats:italic> bioactive peptides with desired biological function.<\/jats:p>","DOI":"10.1371\/journal.pone.0327582","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T17:28:53Z","timestamp":1753205333000},"page":"e0327582","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Different SARS-CoV-2 variants inhibited by RRM designed peptide"],"prefix":"10.1371","volume":"20","author":[{"given":"Uros","family":"Krapez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urska","family":"Kuhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1159-6351","authenticated-orcid":true,"given":"Petra","family":"\u0160enica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigita","family":"Slavec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drasko","family":"Cosic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Loncarevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Janezic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4218-7390","authenticated-orcid":true,"given":"Irena","family":"Cosic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"pone.0327582.ref001","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijbiomac.2022.01.118","article-title":"Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic","volume":"204","author":"RM El-Shabasy","year":"2022","journal-title":"Int J Biol Macromol"},{"issue":"5","key":"pone.0327582.ref002","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3390\/microorganisms9050926","article-title":"Mutation signatures and in silico docking of novel SARS-CoV-2 variants of concern","volume":"9","author":"N Shahhosseini","year":"2021","journal-title":"Microorganisms"},{"key":"pone.0327582.ref003","article-title":"New coronavirus variants could cause more reinfections, require updated vaccines","author":"K Kupferschmidt","year":"2021","journal-title":"Science"},{"issue":"10293","key":"pone.0327582.ref004","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(21)01358-1","article-title":"SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness","volume":"397","author":"Public Health Scotland and the EAVE II Collaborators","year":"2021","journal-title":"Lancet"},{"issue":"16","key":"pone.0327582.ref005","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant","volume":"386","author":"N Andrews","year":"2022","journal-title":"N Engl J Med"},{"issue":"6538","key":"pone.0327582.ref006","doi-asserted-by":"crossref","DOI":"10.1126\/science.abg3055","article-title":"Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England","volume":"372","author":"NG Davies","year":"2021","journal-title":"Science"},{"issue":"12","key":"pone.0327582.ref007","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1109\/10.335859","article-title":"Macromolecular bioactivity: is it resonant interaction between macromolecules?--Theory and applications","volume":"41","author":"I Cosic","year":"1994","journal-title":"IEEE Trans Biomed Eng"},{"issue":"3","key":"pone.0327582.ref008","first-page":"236","article-title":"Virtual spectroscopy for fun and profit","volume":"13","author":"I Cosic","year":"1995","journal-title":"Biotechnology (N Y)"},{"key":"pone.0327582.ref009","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-0348-7475-5","volume-title":"The resonant recognition model of macromolecular bioactivity: Theory and applications","author":"I Cosic","year":"1997"},{"issue":"9","key":"pone.0327582.ref010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0290845","article-title":"Inhibition of \u03b2-lactamase function by de novo designed peptide","volume":"18","author":"A Mishra","year":"2023","journal-title":"PLoS One"},{"issue":"02","key":"pone.0327582.ref011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18483\/ijSci.2558","article-title":"De Novo designed peptide to prevent SARS-CoV-2 interaction with ACE2 receptor on host cells","volume":"11","author":"I Cosic","year":"2022","journal-title":"ijSciences"},{"key":"pone.0327582.ref012","doi-asserted-by":"crossref","unstructured":"Cosic I, Cosic D. Peptides inhibiting COVID-19. 2022.","DOI":"10.18483\/ijSci.2459"},{"issue":"8","key":"pone.0327582.ref013","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2174\/138920111796117436","article-title":"Advances in methods for therapeutic peptide discovery, design and development","volume":"12","author":"E Pirogova","year":"2011","journal-title":"Curr Pharm Biotechnol"},{"issue":"9","key":"pone.0327582.ref014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024809","article-title":"Biological effects of a de novo designed myxoma virus peptide analogue: evaluation of cytotoxicity on tumor cells","volume":"6","author":"TS Istivan","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"pone.0327582.ref015","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1399-3011.1998.tb00665.x","article-title":"Investigations into the cross-reactivity of rabbit antibodies raised against nonhomologous pairs of synthetic peptides derived from HIV-1 gp120 proteins","volume":"52","author":"V Krsmanovic","year":"1998","journal-title":"J Pept Res"},{"key":"pone.0327582.ref016","volume-title":"Peptides immunologically related to proteins expressed by a viral agent, having a sequence of amino acids ordered by means of protein informational method","author":"MTW Hearn","year":"2001"},{"issue":"1","key":"pone.0327582.ref017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01084262","article-title":"In vitro inhibition of the actions of basic FGF by a novel 16 amino acid peptide","volume":"130","author":"I Cosic","year":"1994","journal-title":"Mol Cell Biochem"},{"issue":"03","key":"pone.0327582.ref018","doi-asserted-by":"crossref","first-page":"19","DOI":"10.18483\/ijSci.2459","article-title":"Analysis of UK and South African strains of SARS-CoV-2 using resonant recognition model","volume":"10","author":"I Cosic","year":"2021","journal-title":"ijSciences"},{"key":"pone.0327582.ref019","author":"I Cosic","year":"2021"},{"issue":"07","key":"pone.0327582.ref020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.18483\/ijSci.2495","article-title":"Analysis of Delta (Indian) variant of SARS-CoV-2 infectivity using resonant recognition model","volume":"10","author":"I Cosic","year":"2021","journal-title":"ijSciences"},{"issue":"4","key":"pone.0327582.ref021","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"KJ Livak","year":"2001","journal-title":"Methods"},{"key":"pone.0327582.ref022","doi-asserted-by":"crossref","first-page":"105806","DOI":"10.1016\/j.antiviral.2024.105806","article-title":"TXM peptides inhibit SARS-CoV-2 infection, syncytia formation, and lower inflammatory consequences","volume":"222","author":"T Govednik","year":"2024","journal-title":"Antiviral Res"},{"issue":"20","key":"pone.0327582.ref023","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1111\/bph.16258","article-title":"A novel, label-free, pre-equilibrium assay to determine the association and dissociation rate constants of therapeutic antibodies on living cells","volume":"181","author":"EM Janezic","year":"2024","journal-title":"Br J Pharmacol"},{"issue":"14","key":"pone.0327582.ref024","article-title":"Authors\u2019 correction for Euro Surveill. 2020;25(3)","volume":"25","author":"VM Corman","year":"2020","journal-title":"Euro Surveill"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0327582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T17:28:58Z","timestamp":1753205338000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0327582"}},"subtitle":[],"editor":[{"given":"Ot\u00e1vio Augusto","family":"Chaves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0327582","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]}}}